|
[posting]56138891[/posting]Danke, ich habs (war im annual report und ich habs überlesen): Under the agreement, we received an upfront payment of $3.0 million. Alexion is also required to pay an annual maintenance fee of $0.5 million during the research term of the agreement and $1.0 million during any extension of the research term. In addition, if certain development, regulatory and commercial milestones are achieved, we are eligible to receive up to $66.5 million for the first product to achieve such milestones on a target‑by‑target basis. If licensed products are successfully commercialized, we are also entitled to receive royalties based on a percentage of net sales of such products sold by Alexion, its affiliates or its sub licensees, which percentage is in the low single digits. Alexion’s royalty obligations continue on a product‑by‑product and country‑by‑ country basis until the expiration of the last‑to‑expire valid claim in a licensed patent covering the applicable product in such country. |
|
| aus der Diskussion: | Antikörper-Optimierung durch Xencor |
| Autor (Datum des Eintrages): | Ville7 (09.11.17 09:17:21) |
| Beitrag: | 30 von 268 (ID:56138975) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |